In one paragraphArticle in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
13 authors.
Maria Nuria Peralta-MorenoDepartment of Materials Science and Physical Chemistry, Institut de Recerca en Quimica Teòrica i Computacional (IQTCUB), University of Barcelona (UB), 08028 Barcelona, Spain.ORCID 0000-0002-7762-0406 Yago MenaDepartment of Materials Science and Physical Chemistry, Institut de Recerca en Quimica Teòrica i Computacional (IQTCUB), University of Barcelona (UB), 08028 Barcelona, Spain.
David Ortega-AlarconInstitute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit GBsC-CSIC-BIFI, Universidad de Zaragoza, 50018 Zaragoza, Spain.ORCID 0000-0003-1885-4365 Ana Jimenez-AlesancoInstitute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit GBsC-CSIC-BIFI, Universidad de Zaragoza, 50018 Zaragoza, Spain.ORCID 0000-0003-4726-7821 Sonia VegaInstitute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit GBsC-CSIC-BIFI, Universidad de Zaragoza, 50018 Zaragoza, Spain.
Olga AbianInstitute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit GBsC-CSIC-BIFI, Universidad de Zaragoza, 50018 Zaragoza, Spain.ORCID 0000-0001-5664-1729 Adrian Velazquez-CampoyInstitute of Biocomputation and Physics of Complex Systems (BIFI), Joint Unit GBsC-CSIC-BIFI, Universidad de Zaragoza, 50018 Zaragoza, Spain.ORCID 0000-0001-5702-4538 Timothy M ThomsonCentro de Investigación Biomédica en Red en el Área Temática de Enfermedades Hepáticas Digestivas (CIBERehd), 28029 Madrid, Spain.ORCID 0000-0002-4670-9440 Marta PintoAbbVie Deutschland GmbH & Co. KG, Computational Drug Discovery, Knollstrasse, 67061 Ludwigshafen, Germany.
José M Granadino-RoldánDepartamento de Química Física y Analítica, Facultad de Ciencias Experimentales, Universidad de Jaén, Campus "Las Lagunillas" s/n, 23071 Jaén, Spain.ORCID 0000-0002-9527-1158 Maria Santos TomasDepartment of Architecture Technology, Universitat Politecnica de Catalunya (UPC), Av. Diagonal 649, 08028 Barcelona, Spain.
Juan J PerezDepartment of Chemical Engineering, Universitat Politecnica de Catalunya (UPC), Barcelona Tech. Av. Diagonal, 647, 08028 Barcelona, Spain.ORCID 0000-0002-0748-8147 Jaime Rubio-MartinezDepartment of Materials Science and Physical Chemistry, Institut de Recerca en Quimica Teòrica i Computacional (IQTCUB), University of Barcelona (UB), 08028 Barcelona, Spain.ORCID 0000-0002-5529-2325 Funding
Agència de Gestió d'Ajuts Universitaris i de Recerca 2020PANDE00048Consejo Superior de Investigaciones Científicas COV-006 and COV-201Diputación General de Aragón E45_23R and B25_23RDiputación General de Aragón predoctoral contract 2019ERDF A way of Making Europe PID2021-127296OB-I00Fondo de Investigaciones Sanitarias from Instituto de Salud Carlos III and European Union (ERDF/ESF, "Investing in your future") PI18/00349 and PI21/00394Fondo Investiga COVID-19 from Instituto de Investigación Sanitaria de Aragón IIS-AFPI predoctoral contract BES-2017-080739Fundación hnaMinistry of Science and Innovation MCIN/AEI/10.13039/501100011033/Plan Nacional de I + D PID-107139RB-C21Plataforma Temática Interdisciplinar Salud Global PTI-SG + SGL2103019Spanish Ministry of Economy and Competitiveness BFU2016-78232-PSpanish Structures and Excellence María de Maeztu program CEX2021-001202-MThe Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR)-Generalitat de Catalunya 2021SGR00350Universitat de Barcelona PREDOCS-UB 2020 grant 5760700-IQTC
6 · The paper itselfAbstract
The development of specific antiviral therapies targeting SARS-CoV-2 remains fundamental because of the continued high incidence of COVID-19 and limited accessibility to antivirals in some countries. In this context, dark chemical matter (DCM), a set of drug-like compounds with outstanding selectivity profiles that have never shown bioactivity despite being extensively assayed, appears to be an excellent starting point for drug development. Accordingly, in this study, we performed a high-throughput screening to identify inhibitors of the SARS-CoV-2 main protease (M
Indexed as
Antiviral AgentsCoronavirus 3C ProteasesMolecular Docking SimulationMolecular Dynamics SimulationProtease InhibitorsSARS-CoV-2COVID-19Drug DiscoveryDrug Evaluation, PreclinicalHigh-Throughput Screening AssaysHumansLigandsProtein BindingAntiviral AgentsCoronavirus 3C ProteasesLigandsProtease Inhibitorsdark chemical matterdockingdrug designMMPB/GBSA approachmolecular dynamicsSARS-CoV-2 main proteasevirtual screening
Identifiers
PMID38892306
PMCPMC11172690
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390